![]() |
Illustration Credit: Gerd Altmann |
Overactivation of the immune system leading to circulation of inflammatory proteins around the body contributes to the development of long covid, and could be targeted to provide treatments for patients, finds new research.
Cardiff University research has uncovered biological markers that could be targeted by repurposing medication to treat long covid.
The research conducted extensive analysis of plasma samples obtained from a large cohort of healthy post-covid individuals and non-hospitalized patients with long covid. They found that the complement system – a system that plays a crucial part of the immune system, consisting of a group of proteins that work together to enhance the function of antibodies and immune cells – was commonly overactivated in those with long covid.
“The covid-19 pandemic has left a global legacy of ill health, with long covid estimated to affect up to 1.9 million people in the UK. Long covid can last for months or years after the triggering infection and is associated with diverse symptoms including brain fog, chest pain, breathlessness, fatigue, and sensory problems. The causes of this disease remain largely unknown, emerging evidence suggests an important role for chronic inflammation."
Professor Paul Morgan 'Professor of complement biology, Division of Infection and Immunity